Breast cancer is one of the major causes of mortality in women worldwide. The most aggressive breast cancer subtypes are human epidermal growth factor receptor-positive (HER2) and triple-negative breast cancers. Therapies targeting HER2 receptors have significantly improved HER2 breast cancer patient outcomes. However, several recent studies have pointed out the deficiency of existing treatment protocols in combatting disease relapse and improving response rates to treatment. Overriding the inherent actions of the immune system to detect and annihilate cancer via the immune checkpoint pathways is one of the important hallmarks of cancer. Thus, restoration of these pathways by various means of immunomodulation has shown beneficial effects in...
Recent studies in multiple epithelial cancers have shown thatthe inhibitory receptor programmed cell...
Growing evidence suggests a clear role of the host immune system in HER2+ breast cancer. In addition...
HER-2 is a 185 kDa transmembrane receptor tyrosine kinase that belongs to the EGFR family. HER-2 is ...
Immune checkpoint blockade (ICB)-based therapy is revolutionizing cancer treatment by fostering succ...
The introduction of anti-HER2 therapies to the treatment of patients with HER2-positive breast cance...
PURPOSE: Approximately 20-30% of breast cancer tumors overexpress or amplify human epidermal growth ...
Although the dual anti-HER2 blockade with trastuzumab and pertuzumab monoclonal antibodies has impro...
Overexpression of huHER2 occurs in nearly 15–20% of breast cancers, and it is generally associated w...
Introduction: Overexpression of the receptor tyrosine kinase HER2 has been reported in around 25% of...
HER2-positive (HER2+) breast cancer (BC) is a heterogenous and multifaceted disease, with interestin...
HER2-positive breast cancers may lose HER2 expression in recurrences and metastases. In this work, w...
Immune checkpoints are regulators of immune activation that can be triggered to suppress the immune ...
The discovery and identification of the human epidermal growth factor receptor 2 (HER's-2) genes, ha...
Advances in HER2-targeted therapies have improved the survival of patients with HER2-positive breast...
Breast cancer is the most common neoplasm diagnosed in women around the world. Checkpoint inhibitors...
Recent studies in multiple epithelial cancers have shown thatthe inhibitory receptor programmed cell...
Growing evidence suggests a clear role of the host immune system in HER2+ breast cancer. In addition...
HER-2 is a 185 kDa transmembrane receptor tyrosine kinase that belongs to the EGFR family. HER-2 is ...
Immune checkpoint blockade (ICB)-based therapy is revolutionizing cancer treatment by fostering succ...
The introduction of anti-HER2 therapies to the treatment of patients with HER2-positive breast cance...
PURPOSE: Approximately 20-30% of breast cancer tumors overexpress or amplify human epidermal growth ...
Although the dual anti-HER2 blockade with trastuzumab and pertuzumab monoclonal antibodies has impro...
Overexpression of huHER2 occurs in nearly 15–20% of breast cancers, and it is generally associated w...
Introduction: Overexpression of the receptor tyrosine kinase HER2 has been reported in around 25% of...
HER2-positive (HER2+) breast cancer (BC) is a heterogenous and multifaceted disease, with interestin...
HER2-positive breast cancers may lose HER2 expression in recurrences and metastases. In this work, w...
Immune checkpoints are regulators of immune activation that can be triggered to suppress the immune ...
The discovery and identification of the human epidermal growth factor receptor 2 (HER's-2) genes, ha...
Advances in HER2-targeted therapies have improved the survival of patients with HER2-positive breast...
Breast cancer is the most common neoplasm diagnosed in women around the world. Checkpoint inhibitors...
Recent studies in multiple epithelial cancers have shown thatthe inhibitory receptor programmed cell...
Growing evidence suggests a clear role of the host immune system in HER2+ breast cancer. In addition...
HER-2 is a 185 kDa transmembrane receptor tyrosine kinase that belongs to the EGFR family. HER-2 is ...